CFI-400945 fumarate is primarily used in cancer research due to its role as a selective inhibitor of Polo-like kinase 4 (PLK4). PLK4 is a key regulator of centriole duplication, and its overexpression is often linked to tumorigenesis. By inhibiting PLK4, this compound disrupts centriole formation, leading to mitotic defects and ultimately inducing cancer cell death. It is particularly studied in the context of solid tumors and hematological malignancies. Researchers utilize CFI-400945 fumarate to explore its potential as a therapeutic agent, focusing on its ability to target cancer cells while sparing normal cells. Additionally, it serves as a valuable tool in understanding the molecular mechanisms of PLK4 in cell cycle regulation and cancer progression.